In a study where 18,624 patients were followed worldwide from 2006 to 2008 where half the patients were taking Sanofi-Aventis SA"s and Bristol-Myers Squibb Co."s Plavix [clopidogrel] and the other half were taking AstraZeneca Plc"s experimental blood-thinner Brilinta [ticagrelor], it was found that the Brilinta patients had a 1.4 percent less chance of dying. Although it was also found that the Brilinta patients had less bleeding problems they did suffer from breathing and heart rhythm abnormalities. The main advantage is that Brilinta"s effects wear off in a couple of days allowing patients to undergo surgery immediately whereas as it takes up to 6 days for the effects of Plavix or Effient to wear off. AstraZeneca will apply for US and European regulatory approval in the final quarter of the year and hopes to make it available by the end of 2010
저작권자 © 메디칼업저버 무단전재 및 재배포 금지